Artgen Biotech PJSC, a biotech company, engages in the development of healthcare products in Russia. It develops Betuvax-CoV-2, a vaccine for SARS-COV-2; Tetraflubet, a Flu vaccination; Combi 5V, a Flu + COVID-19 booster vaccine; Betusphere for Immunomodulator; RBT-402, a HPV vaccine; and RBT-501, a vaccine for natural allergy. The company also offers Histograft, a Gene-activated material used as an osteoplastic material, as well as biobanking, genetic research, and regenerative medicine services. In addition, it develops various medical products, such as Xeno-Bone for bone grafting in open operations; Inject-Bone for minimally invasive bone grafting; Inject-Soft use for damage to the skin and mucous membranes; 3D-Bone use for replacement od volumetric bone defects; Cover Bone for guided bone regeneration; and Supl-Bone for bone grafting. The company was formerly known as Public Joint-Stock Company "Human Stem Cells Institute". The company was founded in 2003 and is based in Moscow, Russia.